Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Phenylpropanolamine

This article was originally published in The Tan Sheet

Executive Summary

Phenylpropanolamine: FDA has agreed to investigate assertions by Spray-U-Thin phenylpropanolamine weight-loss spray manufacturer Caprice-Greystoke of a potential conflict of interest involving FDA Office of OTC Drug Evaluation Director Michael Weintraub, MD, who conducted a study for Acutrim maker Ciba Consumer in 1986 on time-release PPA capsules six years before joining FDA. Caprice-Greystoke claims FDA reversed its position on time-release PPA after Weintraub became director of the OTC office. FDA recently told the firm that Weintraub has disqualified himself from the decision-making process on the efficacy of PPA for weight control ("The Tan Sheet" Aug. 7, p. 13)...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084233

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel